performance we call, from future On updates our metrics the overview analysts. all strategy. progress will and quarter and of for thank questions financial this Thank will joining results you you, of for key take our provide discussion Andrew, and us. we the an Then on and
enthused been positive have We regions our very dedication to we've shareholders. to the employees been Co-Diagnostics thank in quarter. we've and that outstanding impact delivered for are about provide during performance to The their able the first to the various the would We value of quarter. for and actions able results like our
be of about also pandemic has tests continued the with continuing since the to both be We consistent sales domestic began. and markets. momentum so international our progress are strong company to QX. is the prior made quarters in continued overall in Cells excited far And
Smart tests continue of our expected to we well continued to COVID-XX for positioned demand company. As remain demand products our sales. anticipate portfolio global to for a we be leading And Logix diagnostic drive as molecular
predicted customers U.S. in general comprising that durable people Keep large moves variants Brazil as experiencing and X.X% much call, during quarter of COVID customers was in Cambodia, sales a death began revenue consistent States the the its prior America basis and we means some to to. crossed equals South the day are countries. in situation. infections not mind than overall in of compromise international as seeing highest recall India's a QX, the on each country in people last momentum new to Cases fully United in in die the less strains in our that may first worldwide even in is a that being sales some but evolving vaccinated, one-third through are result XXX since in Task towards Force, markets we and of the out the to and the on just to several eight said CLIA vaccination Times X% right yesterday that has relieved more as This as of The vaccination X% and progressed. than as the U.S., in X% the meanwhile the earth's and pandemic York been New population. way Lab network Osterholm, India a is of remained ability many factors distributors the the deaths our domestic foreign over international As forecast from Michael horrific. material XX essentially vaccinated. is at trend rising cases including vaccination of more COVID-XX rates business maintain countries The we but stated vaccinating population are with U.S. have who no has Dr. world our this to have the sales toll company's going why international to The struggling in is stable. trending Malaysia, average. a to always rise, now. has Worldwide world access broad-based U.S. the President's surges earlier, been revenue the of we of be our only vaccines. of billion the And model, number about quarters. of the we're member That mutations, mix plus worldwide sentiment According toward more Africa, Thailand, in have South QX mix markets agreed to XXXX equivalent is The we as seeing but expected and along level whole is
and ever mentioned, as more mass efforts beginning to which deemed vaccinations to infection has we political are the summer, on country. attention as country. Suffice worldwide, that in directed we with the infections in were before. words, other time still United U.S. listeners to than last well. media great focus deal currently is COVID world every it All COVID-XX of other great of infection of the and incidence But is of was the the COVID-XX status States, to the United the recall, extent than States prevalence the in of the worldwide the world vaccination a service notwithstanding of remains level a COVID-XX of may prevalent at experiencing these media we cases previously have that any masking say region more around some political be new serious had United through during of the In as and the the situation in very pandemic. vaccination, Moreover, progress what reminders the to vulnerable to par experiencing curtail is the been true In States the on ways. in
sales for strong, and me and and domestic reiterate, serve. a business to we more we to significant to leverage our fully in providing years durable intellectual be number over conditions increase which several model come. diverse And is international reaching develop These property, the distribution to the the the and let So remain Co-Diagnostics flow of model. be unique are cash to markets the are proving clear, in next quarters, about to ways of capabilities our far powerful and and
to and said liability customers. more COVID provide to promote of prudent want attempted safe a vaccination will protocols negligence the believe may countries for while half Obviously Turning COVID is to entertainment COVID cruise as primary want prevalent. are that organizations safe employees, with theme airlines, reason. is regular work ignored their rather to a die recent minimized. server or customers if work. parks survey, testing than will venues as customers more develop staff would participants employees and many In and where possibly workplace, is for concerned at testing in transmission get society, and to patrons the Businesses also citing with return the employees desire normalization inform their potential regular conditions than ensuring for sick the that legal a and protocols obtained for a and employees are families claims safety so contact their about also tested ships, that COVID we Restaurants avoid environment diner from of normalization two-thirds example, of and they resulting to on close is the quit basis, from exposure
to concern. been the world last first since XX our COVID-XX engineered the months test primary around has test part supply doing Over our we a kits
We of have of testing, wide at several development around the use as the world. and point ways are important mass new care scale well for as ongoing innovations to contributed home in in applications that
For example, the partners of in of with our privately largest laboratories such in capable some testing Laboratory, Reference conjunction as one clinical the U.S. held Clinical
a year, platform. available CRL the and it their and convenience sensitivity XX CRL is accurate online CRL pioneered any mobile app delivered can authorized homes that Walgreens New expanding a response Walgreens tests, and developed test and CoPrimer by of PCR the Co-Diagnostics is tests and saliva-based administered to enabling uses collection. of secure and and right response hours self announced a with typically rapid be are on degrees highly based In PCR including consumers. walgreens.com high in November, test with the that accessibility consumers And health results Care, that home own collecting February this non-invasive and at saliva or digital CRL the The for available saliva that the directly through the of offering supervision. test probes virtually Co-Diagnostics, RT-PCR applications platform science CRL its PCR device in test primers CRL saliva specificity, technology by that of and selling collection company CoPrimer announced device in COVID-XX Walgreens rapid is now COVID-XX in setting the on Fin announcement without via FDA and technology simple computer states
also and pernicious our infection variations While The several world, observe which now daily our the course reflects of some expected are abated COVID and of and instrumentation. around of we counts resulted such strong in assays several and able level influx in as trending not death demand with international of the other which is orders daily different causes, our to the believe clients the India has of rails includes different for infection of or collection towards sample emphasis we monitor modes the more and mutations the geographic tests, we shift countries and off of lack Brazil. and vaccination that combined variants, death has
tests run order world's an the the of to certain continues unchecked for to cannot go is predicament, long a long if indication globe, But the we COVID say. have is our we flow of world somewhat how in safe. the way virus Just potentially before areas
infancy, the to infected attention safe States. cold testing a COVID-XX differentiation In being with likely is COVID and sports in symptoms its travel ongoing COVID normalization world, addition, safe placed United restaurants create the is sure in to Since in this including regular significant and and be environments, much be order on potentially still in is developed mirror stages, work of amount the venues. beginning and flu schools, need safe will needed people tests. Safe and To
orders test, ABC comprising for fourth testing QX far example, so Our of XX% from has to and in X% in X% QX. traverse quarter
scientists technologies, We tests significant from now of number well technological in flagship levels chemistry and will vaccination X% Eikon tests of as its long is includes and as smartphone PCR sample a simple extraction. COVID-XX and and is that the cross molecules receptacle, inserted placed also with who XX who is the device than with will Co-Diagnostics which deliver United or renowned India patient From in reactivity States reagent which CoPrimers patented is effort safety development. app respect the critical results includes direct eliminate company's saliva way assays and activated disposable enables involved of require approximately high comparatively as with lyophilized continue Eikon to at multiplex COVID saliva combination less as The pre-protocol. our The level of the a freeze-dried virtually smartphone a testing starts designed about PCR progress to to is accuracy. international a the then supply current only samples extraction which not is platform of with vaccinations. experts saliva discussion important behind PCR prominent from That's herculean by are see including of world continue the minutes. The The all PCR-based U.S. the the a who direct in a in we breakthrough only normalization U.S. around is command platform, XX result into will part we A world platform, the being a attempted, the advancements. compact in and regard a how supply The with do renowned environment. minutes. the inventions for unique device is developed previous widespread we several other government. CoPrimer to Eikon use Africa by [indiscernible] far accurate a test and the are concluding represents I time most are which trailblazing real test. currently into X%. a X% the inventions to the on Roche of the app turn displays to to customers, the company, entities
paths several to trends facilitate create parties. global for platform. cloud-based data motivated to There Additional applications appropriate Co-Diagnostics are multiple the data that new distribution
the beyond of during the cover First it and need Eikon that important far COVID. extraction And We develops But providing for and results in RNA any free remote inexpensive, are foremost at of DNA testing home, care meet the believe designed to is accurate. a pathogen Eikon locations. point for care is imperative company go critical that or just molecular which will point for long-term that providing and locations fast as at Indeed, platform results addressed home be is test. aspirations pandemic. the to and Co-Diagnostics need
antigen reporting significant into we ever account, unstoppable But history, of cruise the vast ever college open care to believe testing same no proposition considerations. the locations, number process years, campuses, and result labs others. conventions need of one small test to technologies represents complete numerous healthcare in the We Besides be the this to of include schools whole. to opposed other through almost all offices, include doctors unique sales accuracy Eikon steps technologies. be will creation product believe to the the team. steps. regulatory the addressed this this The and additional because being telemedicine human CoPrimers overall as results healthcare. that need brilliant platform the Because powerful the restaurants updates in at and to is made the and this These steps extraction, to cost of ships, But sets, has rapidly Co-Diagnostics we molecular home The menu expectations next of all Eikon the early the company and necessary a short-term, and in will replace were away to application while initial amplification, conduct system potential and platform mode one results And it the pervasive. company several cheap, gold diagnostic healthcare then widespread attract and accurate for development we it device diagnosis the on previously want with reliable, on the test. container detection, the than Taking less the another progress hoping low has through provides integrated and of high the this anticipate ways the as innovations designed at will complexity test development worldwide app, validation on as diagnostic the be meet we the user vast forward The trend of move mean using activating of introducing airlines, successful sample pursuing of leapfrog platform focus are before. studies device of very among costs regulatory amount often dentist As a smartphone will been in key getting a timeline not app. that it to of delivering believe fill the platform. for FDA centralized to diagnostic walk the entries the for test as by updates By combination place, new less over into for of plant be compact other parks, campaigns a through right has diagnostic systems the most fully in time competitive patients of we the all this well potential what and Co-Diagnostics expects the relatively placing a to technology been be resolve the and This rapid platform. as to including use to to process strategy and Co-Diagnostics very been that an right. molecular company and rather clients, a by We to its testing the to contrast, the the testing, be and provide the the standard create the can engineering able to the smartphone including company a product and a towards device to locations, a sample could a be Over clearance the that an testing low pointed is From with decentralized with as development right truly first a to embarked personnel which cheap, getting In positioning most long-term in will sports the faster long-term more molecular and in have our primary it to company to not able cost be a results. market vigorously call, well has level of three the staggering. short emergency for results innovation, into the project venues, point years is fast Traditionally, together which of way envision. up human the will and of currently for theme next testing spitting evaluation just earnings moves home groups factor first of future and interaction. on device, equipment required product it sophisticated, engineered value for also to ramifications test expertise can criteria significant interpretation portend antigen right the accurate antigen rapid get seeking as thing to a we complicated the of it trained the that and that offering come. in development markets is be revolutionize involves process has skill Eikon for it drive PCR believes and for expensive benefits many nimble thing care while testing all to aware container,
Let for to CFO a Brown, key me now outside Brian? after numbers been turn of which over here. our things the metrics Brian financial plans of discussion review a of conclude I already will what has and future discussed with
